The effects of doxorubicin and blocking activin receptor 2B ligands in mice [muscle]
Ontology highlight
ABSTRACT: Doxorubicin is a widely used and effective anthracycline chemotherapy drug. However, it causes cardiotoxicity and also a few negative effects on skeletal muscle as well. As a result, cancer treatment might actually worsen cancer-induced cachexia and consequently the prognosis of the disease. Inhibiting myostatin/activin signaling is known to increase muscle size. This pathway blockade by soluble activin receptor IIB (sAcvR2B-Fc) has also prolonged survival in cancer, even of animals in which tumor growth is not inhibited. It is not known, however, whether blocking this pathway affects chemotherapy-induced muscle wasting. We found that doxorubicin induces muscle atrophy which is prevented by a blocker for activin receptor 2B ligands (sAcvR2B-Fc).
ORGANISM(S): Mus musculus
PROVIDER: GSE77745 | GEO | 2016/09/25
SECONDARY ACCESSION(S): PRJNA311341
REPOSITORIES: GEO
ACCESS DATA